Bloomberg News

Roche’s Perjeta for Breast Cancer Wins Approval

June 11, 2012

(Corrects drug spelling in headline, second paragraph of story published June 8.)

Roche Holding AG (ROG)’s personalized drug treatment for a fast-growing type of breast cancer won approval from U.S. regulators.

Perjeta, chemically known as pertuzumab, is designed to work with the Basel, Switzerland-based company’s Herceptin and chemotherapy to attack breast cancer that has spread in patients who have a certain gene mutation. The Food and Drug Administration today cleared Perjeta for consumer use, Roche’s Genentech unit said in a statement.

To contact the reporter on this story: Anna Edney in Washington at

To contact the editor responsible for this story: Reg Gale at

Toyota's Hydrogen Man
blog comments powered by Disqus